Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • mattanswers
    Member
    • Oct 2009
    • 65

    #1

    Cuffdiff dilemma

    I have 4 samples, each in triplicate (A1, A2, A3; B1, B2, B3; C1, C2, C3; D1, D2, D3)

    When I use Cuffdiff to compare within each sample, say A1 to A2 or B2 to B3, I get DE genes and most of the 30K or so genes have FPKM values. This is true for all 12 .bam files, in other words there is a similar result (most genes have FPKM values and status of OK) for all in-sample comparisons.


    When I use Cuffdiff to compare between samples, say A1,A2 to C2,C3 or A1,A2,A3 to D1,D2,D3, I get results only for A1,A2 to B2,B3, but for A2,A3 to B2,B3, the status for almost all genes is NOTEST.

    The only genes with status OK and FPKM values are on mitochondria and chloroplast DNA. This same result occurs for all other between sample comparisons. (Only A1,A2 to B2,B3 works).

    The same merged.gtf and genome.fa files are being used in all Cuffdiff's. Only the accepted_hits.bam files are changing.

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 08-06-2026, 07:41 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-03-2026, 10:13 AM
0 responses
39 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-31-2026, 02:55 AM
0 responses
43 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
27 views
0 reactions
Last Post SEQadmin2  
Working...